Webseite regenold.com

Regulatory News:

Accentus Medical, a leading UK medical technology company that supplies advanced coatings and surface treatments to the medical device industry, announced today that it has signed a Licence and Services Agreement with Zimmer Holdings, Inc., a global market leader in musculoskeletal care. This agreement will enable the use of Accentus Medical's Agluna^® anti-infective technology on a potentially broad range of Zimmer products.

Forbion Capital Partners, a leading investment firm dedicated to the life science sector, today announces the final closings of both FCF I Co-Invest Fund and of FCF II, raising a total of more than €190m ($240m). Forbion's €54m Co-Invest Fund aims to invest alongside FCF I in a select number of late-stage FCF I portfolio companies. FCF II has an investment strategy similar to its predecessor fund FCF I. Forbion aims to invest the majority of the fund in Europe and the remainder in North America and Israel. The investment focus is on private companies developing novel drugs, medical devices and diagnostics for high- or even unmet medical needs. This is serving a market that is both driven by the pharmaceutical industry's continued need for new products to supplement their ailing pipelines as well as by patient demand for safer and more efficacious treatments.

Research and Markets (http://www.researchandmarkets.com/research/2c2bf4/health_and_wellnes) has announced the addition of the "Health and Wellness in Norway" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/e1e09f/health_and_wellnes) has announced the addition of the "Health and Wellness in Greece" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/800c06/health_and_wellnes) has announced the addition of the "Health and Wellness in Finland" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/b4eb0f/health_and_wellnes) has announced the addition of the "Health and Wellness in Denmark" report to their offering.

Die Europäische Kommission hat den Zulassungsantrag für SYCREST^® (Asenapin) Sublingualtabletten für die Behandlung von mittelstark bis stark ausgeprägten manischen Episoden in Zusammenhang mit einer Bipolar-I-Störung bei Erwachsenen bewilligt. Das gab MSD (MSD ist ein Handelsname von Merck & Co., Inc., mit Hauptniederlassung in Whitehouse Station, New Jersey, USA) heute bekannt. Bei der heutigen Entscheidung ist man den Empfehlungen des Ausschusses für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) gefolgt. Die Entscheidung der Kommission gilt für alle 27 europäischen Mitgliedstaaten.

Research and Markets (http://www.researchandmarkets.com/research/79eb51/searle_pakistan_lt) has announced the addition of the "Searle Pakistan LTD.-Detailed Product Pipeline" company profile to their offering.

Research and Markets (http://www.researchandmarkets.com/research/d9793d/pharmatec_pakistan) has announced the addition of the "Pharmatec Pakistan (private) Limited-Detailed Product Pipeline" company profile to their offering.

A group of Glasgow lawyers are swapping the courts for the track, as they are taking part in a sponsored run to raise money for a vital Scottish health service.

"Stay-at-home Economy" is a booming economic activity that focuses on moving, various exercises and physical training without going out. Currently, Deng Shuenn Industrial Co., Ltd has improved the practical efficiency of auxiliary sport equipment, such as the Crazy Fit Massager, Vibration plate training machine and so forth by study from domestic and foreign scholars. It is an alternative choice for those who do not have time for taking exercises, just like white collar workers, SOHO, old-aged and people who find it inconvenient to go outdoors.

Index Ventures today announced that Dr Kevin Johnson has formally expanded his relationship with the firm and has joined the team as a Partner in the Life Sciences team. Dr Johnson will focus specifically on seeking out new assets in the biologics area, which will enable Index Ventures to build companies based on the asset-centric model he and Index pioneered.

MSD (in den USA und Kanada unter dem Namen Merck bekannt) (NYSE:MRK) und Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) gaben heute bekannt, dass die intravenös (IV) verabreichte Formulierung von BRINAVESS™ (Vernakalant) die Marktzulassung in der Europäischen Union (EU), Island und Norwegen für die Konversion von kürzlich begonnenem Vorhofflimmern (VHF bzw. AF) in Sinusrhythmus bei erwachsenen Patienten erhalten hat.

Research and Markets (http://www.researchandmarkets.com/research/ebf598/norway_pharmaceuti) has announced the addition of the "Norway Pharmaceutical Market Analysis, 2010-2014" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/aaaafa/daily_updates_inf) has announced the addition of the "Daily Updates: Inflammatory Diseases - Tracking breaking research, drug development news new trials" subscription to their offering.

Research and Markets (http://www.researchandmarkets.com/research/886118/trends_in_generics) has announced the addition of the "Trends in Generics Industry Ownership: Evaluating Changing Industry Paradigms and Emerging Players" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/a3d4d9/daily_updates_can) has announced the addition of the "Daily Updates: Cancer Immunotherapy - Tracking breaking research, drug development news new trials" subscription to their offering.

Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on Wednesday, September 15, 2010 at 11:40 am Eastern time.

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar^TM (LTX-109) treatment of skin infections caused by Gram positive bacteria.

Market Publishers Ltd informs that new in-demand market reports by GlobalData are available in its catalogue.

Research and Markets (http://www.researchandmarkets.com/research/bca76e/health_grants_info) has announced the addition of the "Health Grants Information Service" subscription to their offering.

Research and Markets (http://www.researchandmarkets.com/research/857fc2/motion_sickness_th) has announced the addition of the "Motion Sickness Therapy Area Pipeline Report" report to their offering.

Research and Markets (http://www.researchandmarkets.com/research/2745c9/argentina_pharmace) has announced the addition of the "Argentina Pharmaceuticals and Healthcare Report Q4 2010" report to their offering.